TY - JOUR
T1 - Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma
AU - Tada, Kohei
AU - Kim, Sung Won
AU - Asakura, Yoshitaka
AU - Hiramoto, Nobuhiro
AU - Yakushijin, Kimikazu
AU - Kurosawa, Saiko
AU - Tajima, Kinuko
AU - Mori, Shin ichiro
AU - Heike, Yuji
AU - Tanosaki, Ryuji
AU - Maeshima, Akiko Miyagi
AU - Taniguchi, Hirokazu
AU - Furuta, Koh
AU - Kagami, Yoshikazu
AU - Matsuno, Yoshihiro
AU - Tobinai, Kensei
AU - Takaue, Yoichi
AU - Fukuda, Takahiro
PY - 2012/8
Y1 - 2012/8
N2 - The outcome after allogeneic hematopoietic stem cell transplantation (allo-HCT) for diffuse large B-cell lymphoma (DLBCL) associated with follicular lymphoma (FL), which includes DLBCL with pre- or co-existing FL, remains controversial, and few previous reports have compared the outcomes after allo-HCT for FL, DLBCL associated with FL, and de novo DLBCL. We retrospectively analyzed 97 consecutive patients with FL (n = 46), DLBCL associated with FL (n = 22), or de novo DLBCL (n = 29) who received allo-HCT at our institute between 2000 and 2010. With a median follow-up of 53 months, the 5-year overall survival (OS) and progression-free survival (PFS) were, respectively, 77% and 70% for FL, 62% and 57% for DLBCL associated with FL, and 26% and 23% for de novo DLBCL. The 5-year cumulative incidences of non-relapse mortality and disease progression/relapse were, respectively, 16% and 15% for FL, 19% and 24% for DLBCL associated with FL, and 36% and 41% for de novo DLBCL. By a multivariate analysis, the OS and PFS for DLBCL associated with FL were significantly better than those for de novo DLBCL, whereas they were not significantly different from those for FL. These results suggest that allo-HCT may be a promising option for patients with not only advanced FL but also DLBCL associated with FL.
AB - The outcome after allogeneic hematopoietic stem cell transplantation (allo-HCT) for diffuse large B-cell lymphoma (DLBCL) associated with follicular lymphoma (FL), which includes DLBCL with pre- or co-existing FL, remains controversial, and few previous reports have compared the outcomes after allo-HCT for FL, DLBCL associated with FL, and de novo DLBCL. We retrospectively analyzed 97 consecutive patients with FL (n = 46), DLBCL associated with FL (n = 22), or de novo DLBCL (n = 29) who received allo-HCT at our institute between 2000 and 2010. With a median follow-up of 53 months, the 5-year overall survival (OS) and progression-free survival (PFS) were, respectively, 77% and 70% for FL, 62% and 57% for DLBCL associated with FL, and 26% and 23% for de novo DLBCL. The 5-year cumulative incidences of non-relapse mortality and disease progression/relapse were, respectively, 16% and 15% for FL, 19% and 24% for DLBCL associated with FL, and 36% and 41% for de novo DLBCL. By a multivariate analysis, the OS and PFS for DLBCL associated with FL were significantly better than those for de novo DLBCL, whereas they were not significantly different from those for FL. These results suggest that allo-HCT may be a promising option for patients with not only advanced FL but also DLBCL associated with FL.
UR - http://www.scopus.com/inward/record.url?scp=84864013058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864013058&partnerID=8YFLogxK
U2 - 10.1002/ajh.23246
DO - 10.1002/ajh.23246
M3 - Article
C2 - 22641292
AN - SCOPUS:84864013058
SN - 0361-8609
VL - 87
SP - 770
EP - 775
JO - American journal of hematology
JF - American journal of hematology
IS - 8
ER -